Page 212 - 2022_02-Haematologica-web

Letters to the Editor
Accepted: October 20, 2021.
Pre-published: October 28, 2021.
Disclosures: SM has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb (not related to this study). MM has received honoraria from Celgene and Sanofi. All other authors declare have no conflicts of interest to disclose.
Contributions: DK, MM and SM designed the study and experiments; DK performed sample preparation and analyzed data; MK performed immunogene panel sequencing analysis; TJ performed coverage analysis of immunogene panel sequencing; GP performed sample preparation; RB and ELM provided the clinical data and study materials; DK, MM and SM wrote the manuscript with the input of other authors; SM supervised the study. All authors read and approved the final manuscript.
Acknowledgment: Amplicon sequencing and Immunogene panel sequencing were performed at the Institute for Molecular Medicine Finland (FIMM) Technology Center, which is supported by Biocenter Finland. The authors also acknowledge IT Center for Science Ltd for computational resources.
Funding: the research was funded by European Research Council (M-IMM project), ERAPerMed consortium JAKSTAT-TARGET, Academy of Finland, Finnish special governmental subsidy for health sciences, research and training, Sigrid Juselius Foundation, Helsinki Institute of Life Sciences Fellow funding, and Cancer Foundation Finland. The HOST study was supported by the US National Heart, Lung and Blood Institute research grant 2R01-HL- 62235 and Signe and Ane Gyllenberg Fundation.
Data sharing statement: all data are available in the Online Supplementary Appendix.
References
1. Lamy T, Moignet A, Loughran TP, Jr. LGL leukemia: from patho- genesis to treatment. Blood. 2017;129(9):1082-1094.
2. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-1913.
3. Melamed A, Witkover AD, Laydon DJ, et al. Clonality of HTLV-2 in natural infection. PLoS Pathog. 2014;10(3):e1004006.
4.Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.
5. Loughran TP, Jr., Coyle T, Sherman MP, et al. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood. 1992;80(5):1116-1119.
6. Thomas A, Perzova R, Abbott L, et al. LGL leukemia and HTLV. AIDS Res Hum Retroviruses. 2010;26(1):33-40.
7.Lee TH, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry. J Clin Virol. 2004;31(4):275-282.
8. Savola P, Kelkka T, Rajala HL, et al. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diag- nosed rheumatoid arthritis. Nat Commun. 2017;8:15869.
9. Kim D, Park G, Huuhtanen J, et al. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nat Commun. 2020;11(1):2246.
10.Kwaan N, Lee TH, Chafets DM, et al. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. J Infect Dis. 2006;194(11):1557- 1564.
11. Savola P, Martelius T, Kankainen M, et al. Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica. 2020;105(12):2757-2768.
12.Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
13. Coppe A, Andersson EI, Binatti A, et al. Genomic landscape char- acterization of large granular lymphocyte leukemia with a sys- tems genetics approach. Leukemia. 2017;31(5):1243-1246.
14. Blokzijl F, de Ligt J, Jager M, et al. Tissue-specific mutation accu- mulation in human adult stem cells during life. Nature. 2016;538(7624):260-264.
15. Mustjoki S, Young NS. Somatic mutations in "benign" disease. N Engl J Med. 2021;384(21):2039-2052.
554
haematologica | 2022; 107(2)